Ocular Therapeutix OCUL Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 87.2%-3.4pp | 87.3%-3.8pp | 88.9%-1.7pp | 89.4%-1.4pp | 90.7%-0.3pp | |
| Operating margin | -575.4%-233pp | -519.8%-250pp | -449.7%-220pp | -402.6%-215pp | -342.2%-189pp | |
| Net margin | -558.2%-235pp | -511.9%-208pp | -447.6%-164pp | -382.5%-156pp | -323.1%-130pp | |
| EBITDA margin | -566.5%-231pp | -511.4%-248pp | -442.4%-219pp | -395.7%-214pp | -335.7%-189pp | |
| Free cash flow margin | -463%-214pp | -417.5%-204pp | -357.5%-163pp | -316.5%-168pp | -248.8%-103pp | |
| Returns | ||||||
| Return on equity | -68.6%-11.4pp | -54.9%+40.4pp | -81.8%+15.1pp | -63.4%+9.3pp | -57.2%-2.0pp | |
| Return on assets | -51%-10.2pp | -42%+12.5pp | -55.4%-2.0pp | -44.8%-1.5pp | -40.8%-6.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | 0.1×-0.1× | 0.1×-0.1× | |
| Inventory turnover | 1.9×0.0× | 2×-0.1× | 2.1×-0.4× | 2.1×-0.2× | 1.9×-0.3× | |
| Liquidity | ||||||
| Current ratio | 14.8×+4.6× | 15.4×+4.7× | 7.9×-5.2× | 10.1×-6.5× | 10.2×-11.2× | |
| Quick ratio | 14.7×+4.6× | 15.3×+4.7× | 7.8×-5.2× | 10×-6.5× | 10.1×-11.2× | |
| Cash ratio | 14×+4.8× | 14.5×+5.0× | 7×-4.8× | 9.1×-6.2× | 9.2×-10.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.2× | 0.1×-0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | |
| Debt-to-assets | 0.1×-0.1× | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Interest coverage | -25.8×-9.4× | -22.8×-10.2× | -20.7×-11.1× | -18.5×-10.8× | -16.3×-9.6× | |
| Per Share | ||||||
| Book value per share | $2.60+65.3% | $3.49+75.4% | $1.40-33.4% | $1.77-22.2% | $1.57-49.2% | |
| Valuation | ||||||
| Market capitalization | $1.84B+58.2% | $2.59B+92.6% | $2.03B+41.0% | $1.45B+60.4% | $1.17B-3.0% | |
| Enterprise value | $1.26B+40.8% | $1.93B+87.7% | $1.77B+62.0% | $1.13B+119% | $892.18M+12.5% | |
| Price / sales | 35.4×+15.9× | 49.8×+28.7× | 36.5×+13.0× | 25.6×+10.8× | 19.5×-0.5× | |
| Price / book | 3.2×-1.2× | 4×-0.3× | 7.9×+3.8× | 4.7×+2.3× | 4.4×+1.4× | |
| EV / sales | 24.1×+9.2× | 37.1×+21.0× | 31.7×+13.9× | 20×+11.5× | 15×+1.7× | |
| Free cash flow yield | -13.1%-0.3pp | -8.4%+1.7pp | -9.8%-1.5pp | -12.4%-2.4pp | -12.7%-5.5pp | |
| Earnings yield | -15.8%+0.8pp | -10.3%+4.1pp | -12.3%-0.2pp | -15%+0.4pp | -16.5%-6.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ocular Therapeutix's profit margins?
- Ocular Therapeutix (OCUL) runs a 87.2% gross margin and a -575.4% operating margin, with a -558.2% net margin.
- Where do Ocular Therapeutix's ratios come from?
- Every ratio is computed from Ocular Therapeutix's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.